Drugs for prophylaxis of Myocardial Infarction
-
Upload
jervinm -
Category
Health & Medicine
-
view
376 -
download
0
Transcript of Drugs for prophylaxis of Myocardial Infarction
![Page 1: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/1.jpg)
Dr. Jervin Mano MD.,
Drugs for prophylaxis of
Myocardial Infarction
![Page 2: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/2.jpg)
OVERVIEW
• Introduction
• Definition
• Epidemiology
• Drugs for primary prevention of MI
• Drugs for secondary prevention of MI
• Cardiac rehabilitation
• Recent advances
• Summary
![Page 3: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/3.jpg)
DEFINITION
• Coronary heart disease(CHD) is defined as myocardial impairment due to imbalance between coronary blood flow & myocardial requirement caused by change in coronary circulation .
• Acute coronary syndrome encompasses both unstable angina & MI
• Myocardial infarction is defined as irreversible necrosis of myocardium secondary to prolonged ischemia.
• Types : NSTEMI , STEMI
329-06-2017
![Page 4: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/4.jpg)
CLINICAL CLASSIFICATION OF MI
• Type 1: Spontaneous myocardial infarction
• Type 2: Myocardial infarction secondary to an ischemic imbalance
• Type 3: Myocardial infarction resulting in death when biomarker values are unavailable
• Type 4a: Myocardial infarction related to percutaneous coronary intervention (PCI)
• Type 4b: Myocardial infarction related to stent thrombosis
• Type 5: Myocardial infarction related to coronary artery bypass grafting (CABG)
![Page 5: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/5.jpg)
EPIDEMIOLOGY
• World :-
• Common in developed countries
• On the rise in developing countries
• 7.2 million deaths
• 12.2% of total deaths
• Highest coronary mortality rate – European region , SEAR .
529-06-2017
![Page 6: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/6.jpg)
INDIA
• Will become the most important cause of death by 2015
• Cases of CHD may increase from about 2.9 crore in 2000 to as many as 6.4 crore in 2015
• Prevalence – urban: 6.4%, rural: 2.5%
• 25.1% of all deaths are due to CAD in urban area
629-06-2017
![Page 7: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/7.jpg)
LARGEST SHARE IN NONCOMMUNICABLEDISEASES
729-06-2017
![Page 8: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/8.jpg)
RISING PREVALENCE AND MORTALITY3
Forecasting the prevalence rate (%) of coronary heart disease (CHD) in India
29-06-2017 8
![Page 9: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/9.jpg)
![Page 10: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/10.jpg)
WHAT INCREASES RISK?
You can’t help it!
• Age:
Men > 45; Women > 55
• Sex
• Race
• Family History
• Personality
You can !!
• ↑ S.Cholesterol
• Smoking
• Hypertension
• Diabetes
• Obesity
• Alcohol
• Physical Inactivity
1029-06-2017
![Page 11: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/11.jpg)
DRUGS FOR PRIMARY PREVENTION OF MI
![Page 12: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/12.jpg)
![Page 13: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/13.jpg)
ASPIRIN
• The results of the randomized trials indicated that, compared with placebo, aspirin was associated with a 32% reduction in myocardial infarction
• A meta-analysis by the Antiplatelet Trialists Collaboration demonstrated that, at low CVD risk, the benefits of aspirin are matched by the risks of major bleeding and haemorrhagic stroke, and therefore aspirin is not indicated
• When considering the use of aspirin, the benefits must be weighed against the possible risks associated with its use
• If there are no contraindications (allergy or history of gastrointestinal haemorrhage), low-dose aspirin (75 mg/day) is recommended for all patients at high risk of developing CVD (≥20% over 10 years), provided the blood pressure is controlled to <150/90 mmHg.
![Page 14: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/14.jpg)
STATINS
• In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) (322), statins reduced the risk of non-fatal MI and fatal coronary heart disease by 36% compared with placebo (P = 0.0005), in patients with hypertension and at least three other cardiovascular risk factors
• The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) trial a lower risk of coronary death and non-fatal myocardial infarction
• The results of the Cholesterol Treatment Trialists Collaboration (332), based on 90 056 patients in 14 randomized trials, showed that statin therapy can reduce the 5-year incidence of coronary events, coronary revascularization by about one-fifth for each mmol-per-litre reduction in LDL-cholesterol
![Page 15: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/15.jpg)
• Meta-analysis of data from statin trials has not shown an excess of adverse symptoms, including muscle pain and various gastrointestinal symptoms, in the treated group. The absolute risks of rhabdomyolysis and liver failure from hepatitis were low.
• Statins are recommended in patients with persistently high serum cholesterol (> 5.0 mmol/l) at high risk of developing CVD (≥20% over 10 years)
• The evidence for efficacy of other lipid-lowering agents in primary prevention is weak.
• The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.At 5 years follow-up, fenofibrate did not significantly reduce the risk of coronary events.
![Page 16: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/16.jpg)
ANTI HYPERTENSIVES
• The ALLHAT trial (288) compared the effects of a calcium-channel blocker or an angiotensin- converting enzyme inhibitor and a diuretic on the incidence of coronary heart disease and other cardiovascular disease events.
• In the absence of any compelling indication, and of major adverse effects , currently available evidence from comparative trials of effi cacy and cardiovascular outcomes supports the use of any one of the following classes of drugs as initial therapy: ACE inhibitor, calcium-channel blocker, or low-dose diuretic.
![Page 17: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/17.jpg)
FIXED DRUG COMBINATION(POLYPILL)
• As many high-risk patients would benefit from treatment with several drugs proven to reduce cardiovascular disease, the notion of a combination pill, using fixed dose formulations of effective drugs has been proposed
• Benefits :- simplify selection of drugs and ensure predefined doses.
• Defects:-overtreating people who are at low cardiovascular risk and undertreating people at substantial risk.
![Page 18: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/18.jpg)
HORMONE REPLACEMENT
• hormone therapy had been proposed for prevention of cardiovascular disease in women
• This practice has been called into question following publication of the results of several randomized clinical trials, which showed no coronary protection, and the Women’s Health Initiative, which indicated that long-term use of oestrogen plus progestin was associated with increased risks of cancer and cardiovascular disease.
![Page 19: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/19.jpg)
WHO RISK PREDICTION CHART
![Page 20: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/20.jpg)
WHO RISK PREDICTION CHART
![Page 21: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/21.jpg)
10-YEAR RISK OF CARDIOVASCULAR EVENT > 30%
• Antiplatelet
• Low dose aspirin 75- 150 mg
• Lipid lowering
• Serum cholesterol should be reduced to less than 5.0 mmol/l (LDL-cholesterol to below 3.0 mmol/l), or by 25%
• Statin is the preferred drug
• Anti hypertensives
• If persistent blood pressure ≥130/80 mmHg
• A low-dose thiazide like diuretic, ACE inhibitor, or calcium channel blocker
![Page 22: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/22.jpg)
10-YEAR RISK OF CARDIOVASCULAR EVENT 20–30%
• Antiplatelet
• Aspirin not recommended as risk outweighs benefit
• Lipid lowering drugs
• If >40 years with persistently high serum cholesterol (> 5.0 mmol/l), and or LDL-cholesterol > 3.0 mmol/l, despite a lipid-lowering diet
• Statins preferred
• Anti hypertensive
• If persistent blood pressure ≥140/90 mmHge despite life style strategies with professional assistance within 4–6 months
• A low-dose thiazide- like diuretic, ACE inhibitor, or calcium-channel blocker is recommended as first line therapy.
![Page 23: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/23.jpg)
DRUGS FOR SMOKING CESSATION
• Nicotine replacement therapy
• Bupropion
• Varenicline
![Page 24: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/24.jpg)
DRUGS FOR SECONDARY PREVENTION OF MI
![Page 25: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/25.jpg)
• Antiplatelets
• Aspirin
• Clopidogrel
• Prasugrel
• Ticagrelor
• Anticoagulants
• Warfarin
• Rate limiting agents
• β blockers
• Ca2+ channel blockers
• Inhibition of Renin-Angiotensin-Aldosterone axis
• ACE inhibitors
• ARBs
• Aldosterone antagonists
• Lipid management
• HMG CoA reductaseinhibitors
• Misc
CLASSIFICATION
![Page 26: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/26.jpg)
MECHANISM OF ANTI-PLATELET ACTIVITY
• Class I - ASA, NSAIDs & sulfinpyrazone
• block CO (cyclo-oxygenase)
• Class II - Dypyridamole
• inhibits phosphodiesterase-mediated breakdown of cyclic AMP
• prevents platelet aggregation
• Class III - Thienopyridines
• block binding of ADP to platelet receptor P2Y12 therby inhibiting adenylyl cyclase
• Class IV - antibody, peptide & small molecule IIb/IIIA receptor inhibitors
![Page 27: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/27.jpg)
ASPIRIN
• Acetylsalicylic acid
• NSAID - Analgesic , antipyretic, anti inflammatory, antiplatelet.
• One of the most widely used medications –40,000 tones/ yr
• Largest body of evidence of any drug used in secondary prophylaxis of MI
![Page 28: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/28.jpg)
ASPIRIN
• Antiplatelet drug
• MOA:
![Page 29: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/29.jpg)
ASPIRIN
• Evidence : Antiplatelet Trialists’ Collaboration
• Dosage : post MI – 75-150mg/day
• ADR :
• GI symptoms
• Tinnitus
• Reye’s syndrome
• Toxicity
![Page 30: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/30.jpg)
ASPIRIN
• Resistance :
• 25% population
• Due to non compliance, PD,PK , biochemical factors
• Aspirin resistant group has 4 times greater risk for recurrent infarction
![Page 31: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/31.jpg)
CLOPIDOGREL
• 2nd generation thienopyridine
• Prodrug – requires activation
• MOA : irreversible inhibitor of platelet – P2Y12 receptors
• Dosage : 75mg/day
• Evidence :
• CURE
• CHARISMA
• COMMIT/CCS-2
• CAPRIE
![Page 32: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/32.jpg)
CLOPIDOGREL
• Resistance :
• Genetic polymorphisms in the CYPs involved in the metabolic activation of clopidogrel. –CYP2C19
![Page 33: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/33.jpg)
PRASUGREL
• 3rd generation thienopyridine
• Advantages over clopidogrel
• All the absorbed drug is activated
• Onset of action is rapid
• Greater & predictable action
• CYP2C19 polymorphisms doesn’t affect much
• MOA : irreversible inhibitor of platelet – P2Y12 receptors
![Page 34: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/34.jpg)
PRASUGREL
• Dosage : loading – 60mg , maintenance – 10mg
• ADR : increased risk of bleeding , not used in Cerebrovascular diseases
• Evidence : TRITON-TMI 38
![Page 35: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/35.jpg)
TICAGRELOR
• MOA : reversible oral P2Y12 receptor inhibitors
• Twice daily dosing necessary
• Evidence : PLATO – mortality was less in patients randomised to ticagrelor,
• Significant reduction in stent thrombosis, MI & death from any cause
• ADR :
• Bleeding , Dyspnoea
• Adverse cardiac & pulmonary function
• Bradycardia
• Increased conc.of uric acid & creatinine
![Page 36: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/36.jpg)
ANTICOAGULANTS- WARFARIN
• MOA : inhibits vitamin K-reductase-> inhibit synthesis of Factors II, VII, IX & X
• Evidence :
• WARIS
• ASPECT
• CARS
• Trials examining the use of warfarin post-MI have yielded inconsistent results but most studies report an excess of haemorrhagic complications
![Page 37: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/37.jpg)
• Indications:
• Atrial fibrillation
• LV thrombus, aneurysm
• Severe dilated LV
• History of thrombo-embolism
• ADR :
• Haemorrhage
• Teratogenic
• Transient alopecia
• Dermatitis, diarrhoea
![Page 38: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/38.jpg)
• β receptor antagonist
• Cardioprotective effect by
• Antihypertensive effect –inhibiting vascular Adrreceptors, ↓ Renin Angiotensin production
• ↓ Myocardial demand & Cardiac contractility
• ↓ HR -> ↑ diastolic coronary perfusion
• Antiarrythymic property →Improve left ventricular structure and function
β- BLOCKERS
![Page 39: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/39.jpg)
β- BLOCKERS
• Evidence :
• Norwegian Multicenter study- Timolol
• B-hat – Propranolol
• CAPRICON- CArvedilol Post infaRct survival COntRoling LV dysfunctioN
• COMMIT/CCS-2
![Page 40: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/40.jpg)
![Page 41: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/41.jpg)
β- BLOCKERS
• Drugs : Carvedilol, Metoprolol, Bisoprolol
• Guidelines : SIGN & NICE – start early as possible , lifelong
• ADR:
• Fatigue
• Can exacerbate Raynaud’s phenomenon, severe peripheral vascular disease
• Bradycardia
• AV-block
• Precautions – Asthma, COPD, DM
![Page 42: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/42.jpg)
CALCIUM CHANNEL BLOCKERS
• Indication : Normal ventricular function & when beta blockers are contraindicated
• Drugs : verapamil , diltiazem
• MOA: Ca2+ channel blockade
• ADR:
• Constipation
• Bradycardia
• Accentuate conduction deficits
![Page 43: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/43.jpg)
CALCIUM CHANNEL BLOCKERS
• Guidelines :
• SIGN – only for hypertension post MI
• NICE- Normal ventricular function & when beta blockers are contraindicated
![Page 44: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/44.jpg)
ACE - INHIBITORS
• MOA: ↓ cardiac preload, after load without causing reflex tachycardia
• positive effects on post infarct remodelling & endothelial function
• block local mediators of thrombosis.
• Evidence : HOPE trial
• Guidelines : SIGN – Unless CI long term Rx is recommended in post MI with or without LV dysfunction
![Page 45: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/45.jpg)
![Page 46: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/46.jpg)
• ADR : Dry cough , angioedema, hyperkalemia
• Precautions :
• Aortic stenosis
• severe b/l renal artery stenosis
• Renal disease
![Page 47: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/47.jpg)
ARBS
• MOA : blocks the AT II receptors
• Evidence : VALIANT study – non inferiority of the ARB valsartan when compared head-to-head with an ACE inhibitor
• Guidelines : ARBs are prescribed only when ACE inhibitors are contraindicated
• ADR : Hypotension, hyperkalemia, teratogenic
![Page 48: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/48.jpg)
LIPID MANAGEMENT- STATINS
• MOA: Inhibition of HMG-CoA reductase -> ↓ Cholesterol synthesis, enhances elimination of LDL cholesterol
• Additional cardio protective anti inflammatory activity
• Evidence : Heart protection study : ↓ rate of vascular deaths, major vascular events in high risk patients
• Guidelines : SIGN & NICE : statin therapy for all post MI patients
![Page 49: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/49.jpg)
• ADR : elevated liver enzymes , myopathy
• Precautions : patients with liver disease , high alcohol intake
• Alternate lipid lowering agents
• Fibrates
• Nicotinic acid
• Ezetimibe
![Page 50: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/50.jpg)
NITRATES
• Only used in acute MI to relieve cardiac pain due to continuing myocardial ischemia .
![Page 51: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/51.jpg)
HORMONE REPLACEMENT THERAPY
• Earlier Observational studies showed post menopausal women on HRT have 40-50% lower incidence of cardiovascular events
• HERS – no significant difference
• Increased risk for Ca. Breast .
![Page 52: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/52.jpg)
WHEN TO START DRUG TREATMENT
Beta-blockers, Antiplatelet drugs (aspirin) and ACE inhibitors
• should be initiated whilst patients are in hospital as there is evidence to support benefit following early initiation.
• If this does not happen then primary care clinicians should initiate them as soon after discharge as possible
![Page 53: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/53.jpg)
WHEN TO START DRUG TREATMENT
• Although there is no evidence of the long-term benefit from the use of statins initiated prior to 12 weeks post-infarct, many patients will have been taking statins prior to admission or will have them initiated in hospital.
• All patients discharged from hospital who are not already taking a statin should be assessed and have treatment initiated 12 weeks after a myocardial infarction (A)
![Page 54: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/54.jpg)
CONTINUATION OF TREATMENT
• The treatment durations, for which there is at least one trial that provides direct support, are
• three and a half years for antiplatelet drugs (aspirin)
• four years for beta-blockers and ACE inhibitors and
• six years for statins.
• In the absence of a clear reason to stop treatment it seems reasonable to continue treatment indefinitely.
![Page 55: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/55.jpg)
PATIENTS WITH POST MI ARRYTHYMIAS
![Page 56: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/56.jpg)
AMIODARONE
• 4-18% of patients with a/c MI go for fatal VF in 24-48 hrs
• 75% of sudden death deaths due to MI is due to ventricular tachycardia/fibrillation
• MOA:
• Class III Antiarrhythmic
• Mild beta blocking, Ca blocking activity
• Na2+ channel blocking activity
• Dosage : 100mg/day – AF ; 300mg/day- VT,VF
![Page 57: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/57.jpg)
AMIODARONE
• Evidence : CAMIAT, EMIAT
• Guidelines : SIGN - Patients with documented ventricular arrhythmias
• ADR :
• Heart block – in pre existing SA, AV node disease
• Pulmonary disease
• Hepatitis
• Photodermatitis
• Corneal microdeposits
• Thyroid disorders
• Increased LDL levels
![Page 58: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/58.jpg)
PATIENTS WITH PRIOR MYOCARDIAL INFARCTION WHO HAVE DIABETES
![Page 59: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/59.jpg)
INSULIN OR OHA
• There is evidence that intensive insulin therapy initiated soon after admission for acute myocardial infarction reduces mortality.
• Mellbin et al.- insulin Rx is inferior to Oral hypoglycemic drugs (DIGAMI II)
![Page 60: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/60.jpg)
PATIENTS WITH PRIOR MI AND HEART FAILURE
![Page 61: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/61.jpg)
LONG TERM TREATMENT
All patients should be offered long term treatment with
• an ACE inhibitor and
• then a Beta-blocker (not all beta-blockers have a licence for this indication).
• In addition they should be treated with an antiplatelet drug (aspirin).
• Patients who have moderate or severe heart failure (New York Heart Association (NYHA) grade 3 or 4) should be treated with Spironolactone.
• All of these treatments are cost effective
![Page 62: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/62.jpg)
CONTINUATION OF TREATMENT
• Based on the evidence from the trials, treatment should continue long term. The treatment durations, for which there is at least one trial that provides direct support,
• are 3 ½ yrs for ACE inhibitors
• 2 ½ years for Beta-blockers
• 2 years for Spironolactone
• In the absence of a clear reason to stop treatment it seems reasonable to continue treatment indefinitely.
![Page 63: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/63.jpg)
EPLERENONE
• Potassium sparing diuretic
• MOA: aldosterone antagonist - selective for mineralocorticoid receptor
• Indication : heart failure & LV dysfunction post MI
• ADR : hyperkalemia, hypotension
![Page 64: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/64.jpg)
CARDIAC REHABILITATION PROGRAMS
© CONTINUING MEDICAL IMPLEMENTATION …...BRIDGING THE CARE GAP
• Definition
• “the enhancement and maintenance of cardiovascular health through individualized programs designed to optimize physical, psychological, social, vocational and emotional status”.
• May include multifactorial secondary prevention
• defined as “the sum total of all interventions, both physiological and behavioral, designed to favorably modify an individual’s lifestyle, and enhance adherence and compliance with long-term behaviors compatible with minimizing disease progression”.
![Page 65: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/65.jpg)
RECENT ADVANCES
• Newer antiplatelets –
• Ticagrelor
• Terutroban – pIII – thrombaxane Rs antagonist
• Thrombin Rs antagonist
• Vorapaxar – waiting for approval
• Protease activating Rs-1 antagonist
• ACE inhibitors
• Alacepril
• Movetipril
![Page 66: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/66.jpg)
RECENT ADVANCES
• ARBs
• Azilsartan - app
• Tasosartan - pIII
![Page 67: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/67.jpg)
RECENT ADVANCES
Hypolipidemic agents
• CETP inhibitors
• MOA - inhibit cholesterylester transfer protein (CETP), which facilates transfer of cholesteryl esters from HDL to VLDL or LDL
• Anacetrapib- pIII
• Evacetrapib- pIII
• Torcetrapib- excess deaths in phase III.
• Dalcetrapib – failed – no meaningful efficacy
• ???
![Page 68: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/68.jpg)
RECENT ADVANCES
• Squalene synthase inhibitors
• Apo A-1 Milano
• AGI- 1067
• Monoclonal antibodies
• Alirocumab
• AMG-145 – pIII
• Darapladib - pIII
• Inhibits lipoprotein associated phospholipase A2
![Page 69: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/69.jpg)
NEWER THERAPIES
• Stem cell treatment :
• Coronary artery injections of stem cells derived from their own bone marrow after a myocardial infarction show improvements in left ventricular ejection fraction and end-diastolic volume .
• Clinical trials of progenitor cell infusion as a treatment approach to ST elevation MI are proceeding
![Page 70: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/70.jpg)
NEWER THERAPIES
• Biomaterial and tissue engineering
1. Polymeric left ventricular restraints in the prevention of heart failure
2. in vitro engineered cardiac tissue, which is subsequently implanted in vivo.
3. Injecting cells and/or a scaffold into the myocardium to create in situ engineered cardiac tissue
![Page 71: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/71.jpg)
SUMMARY
• Primary prevention
• Lifestyle modification – a important stay of Rx
• Secondary prophylaxis
• Future
![Page 72: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/72.jpg)
REFERENCE
• Harrison’s principles of internal medicine , 18th edition
• Goodman and Gilman's the pharmacological basis of therapeutics 12th edition
• Basic & Clinical pharmacology , 12th Ed., Betram g. Katzung
• Oxford textbook of medicine 4th edition
• Principles of Pharmacology 2nd edition, HL Sharma KK Sharma
• Lang, Ninian, and Keith Fox. "Current drug therapies for the secondary prevention of MI." Prescriber 19.1 (2008): 14-25.
• Sign guidelines no 41
• Matzke, Gary R., Barbara G. Wells, and L. Michael Posey, eds.Pharmacotherapy: a pathophysiologic approach. New York, NY: McGraw-Hill, 2005.
![Page 73: Drugs for prophylaxis of Myocardial Infarction](https://reader033.fdocuments.us/reader033/viewer/2022051521/5a6542de7f8b9a10228b481d/html5/thumbnails/73.jpg)